RAB17 and cancer: In various cancers, RAB17 acts context-dependently: it is inhibited by ERK2 (Extracellular Signal-Regulated Kinase 2) to facilitate breast cancer cell migration [14], suppresses hepatocellular carcinoma progression [15], and contributes to paclitaxel resistance in ovarian cancer [16].